Skip to content

LaCroix and colleagues [1] recently reported health outcomes after stopping therapy among postmenopausal women randomized to conjugated equine estrogens (CEE) in the estrogen-only arm of the Women’s Health Initiative. A total of 7645 women (78% of the original cohort) gave consent to be included in this follow-up over a mean duration of 10.7 years. Post-intervention use of estrogen replacement therapy (ERT) in the two groups was 3% and 2.7%, respectively. Post-intervention annualized rates comparing women originally randomized to CEE with those randomized to placebo were reported for the following conditions: coronary heart disease: hazard ratio (HR) 0.97, 95% confidence interval (CI) 0.75–1.25; breast cancer: HR 0.75, 95% CI 0.51–1.09; stroke: HR 0.89, 95% CI 0.64–1.24; venous thrombosis: HR 0.63, 95% CI 0.41–0.98; hip fracture: HR 1.27, 95% CI 0.88–1.82. Over the entire follow-up period (i.e. the active treatment intervention phase [i]and[/i] the post-intervention follow-up), the incidence of breast cancer was lower in the CEE group (HR 0.77, 95% CI 0.62–0.95).

Author(s)

  • Rodney J. Baber
    Associate Professor of Obstetrics and Gynaecology at The University of Sydney, Head, Menopause Unit, The Royal North Shore Hospital of Sydney, New South Wales, Australia

Citations

  1. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy. JAMA 2011;305:1305-14.
    http://www.ncbi.nlm.nih.gov/pubmed/21467283
  2. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Womens Health Initiative randomized control trial. JAMA 2004;291:1701-12.
    http://www.ncbi.nlm.nih.gov/pubmed/15082697
  3. Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause 2007;14:373-84.
    http://www.ncbi.nlm.nih.gov/pubmed/17438515
  4. Rossouw J, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since the menopause. JAMA 2007;297:1465-77.
    http://www.ncbi.nlm.nih.gov/pubmed/17405972
  5. Sturdee DW, Pines A; International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011;14: in press
  6. Salpeter SR, Cheng J, Thabane L, et al. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med 2009; 122:1016-22.
    http://www.ncbi.nlm.nih.gov/pubmed/19854329
  7. Hodis HN, Mack WJ. Coronary heart disease and hormone replacement therapy after the menopause. Climacteric 2009;12(Suppl 1):71-5.
    http://www.ncbi.nlm.nih.gov/pubmed/19811246
  8. Postmenopausal hormone therapy: An Endocrine Society Scientific Statement. J Clin Endocrinol Metab 2010;95(Suppl 1):No 07.
    http://www.endo-society.org/journals/scientificstatements/
  9. Hulley SB, Grady D. The WHI estrogen-alone trial do things look any better? JAMA 2004;291:1769-71.
    http://www.ncbi.nlm.nih.gov/pubmed/15082705
  10. Jungheim ES, Colditz GA. Short term use of unopposed estrogens: a balance of inferred risks and benefits. JAMA 2011;305:1354-5.
    http://www.ncbi.nlm.nih.gov/pubmed/21467291
International Menopause Society

Install International Menopause Society - DEV

Install this application on your home screen for quick and easy access when you’re on the go.

Just tap then “Add to Home Screen”

DBS Check Online Certified